SPECIAL NOTICE
99 -- This funding opportunity announcement is a broad agency announcement (BAA) through the fiscal year 2022 (FY22) Defense Medical Research and Development Program (DMRDP) for the Battlefield Wound Management and Infection Research (BWMIR)
- Notice Date
- 9/22/2022 8:09:20 AM
- Notice Type
- Special Notice
- Contracting Office
- W4PZ USA MED RSCH ACQUIS ACT FORT DETRICK MD 21702-5014 USA
- ZIP Code
- 21702-5014
- Solicitation Number
- W81XWH22DMRDPBWMIRBAA
- Response Due
- 11/16/2022 8:59:00 PM
- Point of Contact
- CDMRP Help Desk, Phone: 3016825507, Grants.gov Helpdesk, Phone: 800-518-4726; International 1-606-545-5035
- E-Mail Address
-
help@eBRAP.org, support@grants.gov
(help@eBRAP.org, support@grants.gov)
- Description
- This funding opportunity announcement is a broad agency announcement (BAA) through the fiscal year 2022 (FY22) Defense Medical Research and Development Program (DMRDP) for the Battlefield Wound Management and Infection Research (BWMIR) Award.� For the remainder of the announcement, this BAA will be referenced as the DMRDP BWMIR.� Specific submission information and additional administrative requirements can be found in the document titled �General Submission Instructions,� available in Grants.gov along with this BAA. This BAA for DMRDP is intended to solicit extramural research and development ideas using the authority provided by United States Code, Title 10, Section 4001 (10 USC 4001).� This BAA is issued under the provisions of the Competition in Contracting Act (CICA) of 1984 (Public Law�98-369), as implemented in Federal Acquisition Regulation (FAR) 6.102(d)(2) and 35.016 and in Department of Defense Grant and Agreement Regulations (DoDGARs) 22.315.� In accordance with FAR 35.016, projects funded under this BAA must be for applied research not related to the development of a specific system or hardware procurement.� Research and development funded through this BAA is intended and expected to benefit and inform both military and civilian medical practice and knowledge.� This BAA is intended for extramural applicants only.� For definitions and additional information, see Section II.C.1, Eligible Applicants. �Intramural applicants applying through intramural organizations should use the separate funding opportunity announcement that is available through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org/ under funding opportunity number W81XWH-22-DMRDP-BWMIR. https://apply07.grants.gov/apply/jsf/opportunity/manageOpportunity.faces?oppId=343685 Proposals/applications to the FY22 Joint Program Committee 2/Military Infectious Diseases Research Program (JPC-2/MIDRP) and JPC-6/Combat Casualty Care Research Program (CCCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by 10 USC 4001. �As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test and Evaluation (RDT&E) appropriation. �The U.S. Army Medical Research and Development Command (USAMRDC) Congressionally Directed Medical Research Programs (CDMRP) provides DMRDP execution management support for DHP core research program areas, including the JPC-2/MIDRP and JPC-6/CCCRP. �This funding opportunity announcement and subsequent awards will be managed and executed by CDMRP on behalf of the JPC-2/MIDRP and JPC-6/CCCRP. The JPC-2/MIDRP and JPC-6/CCCRP are two of three major research program areas within the DHP. �The JPC-2/MIDRP and JPC-6/CCCRP are committees of Department of Defense (DOD) and non-DOD medical and military technical experts in combat casualty care- and infectious disease-related program areas. The MIDRP strives to defeat infection by developing solutions to prevent, treat, and diagnose naturally occurring infectious disease threats to eliminate their impacts on operational readiness of DOD personnel. �Prevention is the most desirable infectious disease countermeasure because it prevents disease from occurring (versus treatment post-infection), is the most cost-effective approach, and reduces casualty rates. �Improved diagnosis and treatment of infectious disease casualties is necessary to protect the U.S. Armed Forces. �Due to the ever-increasing resistance to presently available treatments, continued countermeasure developments need to be pursued.� The vision of the MIDRP wound infections capability area is to conduct basic and applied research leading to the development of rapid identification, prevention, and effective treatment solutions to mitigate complications from multidrug-resistant wound infections in multi-domain operations (MDOs) and during prolonged care.� However, without understanding how current standard of care interventions work best to prevent, delay, or treat infection, MIDRP cannot lead and develop new medical countermeasures. The CCCRP strives to optimize survival and recovery from combat-related injury in current and future operational scenarios.� This is accomplished through the development of knowledge and materiel solutions for the acute and early management of combat-related trauma; including point-of-injury, en route, and forward surgical care.� Service Members face many threats in hostile fire arenas, whether conducting large-scale mechanized warfare, low-intensity conflicts, or operations other than war. �Military casualties may wait for hours before definitive health care can be provided. �Furthermore, initial treatment and subsequent evacuation may occur in austere environments characterized by limited supplies and limited diagnostic and life-support equipment, and provision of acute and critical care is labor-intensive and must frequently be provided by non-physician medical personnel. �The primary challenge for combat casualty care research is to overcome these limitations by providing biologics, pharmaceuticals, and devices that enhance the capability of first responders to effectively treat casualties as close to the geographic location and time of injury as possible, with a reduced logistical footprint. The overarching gap in battlefield wound management and infection research is in understanding the complex physiology of combat traumatic wounds to guide researchers and physicians in their efforts to better manage these wounds and limit infection. �The DOD seeks to address this gap through refined preclinical and clinical studies to inform clinical practice guidelines aimed at delivering better care for these devastating wounds. The DMRDP BWMIR Award will support the research and development of materiel and knowledge products to address critical gaps in combat traumatic wound management and control of infection, in operational environments. �Specifically, research that supports the understanding of physiological processes of combat-associated traumatic wounds and infections in preclinical and clinical models represents a key priority for the JPC-2/MIDRP and JPC-6/CCCRP. �The Focus Areas below broadly describe areas of particular interest for funding under the FY22 DMRDP BWMIR. �To meet the intent of the award mechanism, proposals/applications submitted to the FY22 DMRDP BWMIR must address at least one of the FY22 DMRDP BWMIR Focus Areas listed below.� Research not aligned to at least one Focus Area will not be considered for funding. �Selection of the appropriate FY22 DMRDP BWMIR Focus Area(s) is the responsibility of the applicant.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/fc703d7f14ca418e8621408af65243f5/view)
- Record
- SN06475108-F 20220924/220922230116 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |